MOMC-2. Glioblastoma Metabolic Symbiosis: When Lactate Takes The Lead. (5th July 2021)
- Record Type:
- Journal Article
- Title:
- MOMC-2. Glioblastoma Metabolic Symbiosis: When Lactate Takes The Lead. (5th July 2021)
- Main Title:
- MOMC-2. Glioblastoma Metabolic Symbiosis: When Lactate Takes The Lead
- Authors:
- Guyon, Joris
Larrieu, Claire
Bouchez, Cyrielle
Moncada, Ignacio Fernandez
Coffe, Aurelien
Nikolski, Macha
Bikfalvi, Andreas
Daubon, Thomas - Abstract:
- Abstract: Glioblastoma (GBM) is a common and devastating brain tumor, associated with a low median survival, despite standard therapeutic management. Among its major features, GBMs are highly angiogenic and exhibit paradoxically an elevated glycolysis. Most of differentiated cells convert glucose into pyruvate that enters into the Krebs cycle to maximize energy production in the presence of oxygen. For cancer cells, glucose uptake and catabolism are increased regardless of oxygen level. However, their energy needs are important – mainly for rapid growth – that it requires a much faster production flow. It is at this step that lactate dehydrogenase (LDH) are involved: LDHA converts efficiently pyruvate into lactate and generates NAD + to maintain glycolysis. Thus, the lactate formed is exported into the extracellular compartment inducing an unfavourable acidification of the microenvironment. Moreover, LDHB, another LDH isoform, metabolizes lactate into pyruvate for generating energy in mitochondria. Though LDHA has already been studied in many cancers including GBM, the simultaneous role of LDH enzymes have not yet been investigated in GBM development. Hypoxia-driven LDHA expression and lactate production increased cell invasion. Infusing 13C-lactate in starved cells rescued TCA cycle. Then, we showed that, under hypoxia, double sgLDHA/B cell growth and invasion was dramatically decreased in comparison to control cells, mainly caused by an increase in apoptosis. Moreover,Abstract: Glioblastoma (GBM) is a common and devastating brain tumor, associated with a low median survival, despite standard therapeutic management. Among its major features, GBMs are highly angiogenic and exhibit paradoxically an elevated glycolysis. Most of differentiated cells convert glucose into pyruvate that enters into the Krebs cycle to maximize energy production in the presence of oxygen. For cancer cells, glucose uptake and catabolism are increased regardless of oxygen level. However, their energy needs are important – mainly for rapid growth – that it requires a much faster production flow. It is at this step that lactate dehydrogenase (LDH) are involved: LDHA converts efficiently pyruvate into lactate and generates NAD + to maintain glycolysis. Thus, the lactate formed is exported into the extracellular compartment inducing an unfavourable acidification of the microenvironment. Moreover, LDHB, another LDH isoform, metabolizes lactate into pyruvate for generating energy in mitochondria. Though LDHA has already been studied in many cancers including GBM, the simultaneous role of LDH enzymes have not yet been investigated in GBM development. Hypoxia-driven LDHA expression and lactate production increased cell invasion. Infusing 13C-lactate in starved cells rescued TCA cycle. Then, we showed that, under hypoxia, double sgLDHA/B cell growth and invasion was dramatically decreased in comparison to control cells, mainly caused by an increase in apoptosis. Moreover, double impairment of LDHA and B significantly reduced tumor growth and cell invasion, and induces a massive increase in mouse survival. Tracing experiments with 13C-Glucose coupled with RNA sequencing revealed how metabolism adapts to these contraints, by modifying electron transport chain subunit expressions or by increasing lipid droplet formation. Considered for a long time as a metabolic waste, lactate is shown here to play a critical role in GBM cell symbiosis. This study highlighted GBM adaptability through the LDH isoforms and their involvement in GBM development. … (more)
- Is Part Of:
- Neuro-oncology advances. Volume 3(2021)Supplement 2
- Journal:
- Neuro-oncology advances
- Issue:
- Volume 3(2021)Supplement 2
- Issue Display:
- Volume 3, Issue 2 (2021)
- Year:
- 2021
- Volume:
- 3
- Issue:
- 2
- Issue Sort Value:
- 2021-0003-0002-0000
- Page Start:
- ii3
- Page End:
- ii3
- Publication Date:
- 2021-07-05
- Subjects:
- 616.99481
- Journal URLs:
- https://academic.oup.com/noa ↗
http://www.oxfordjournals.org/ ↗ - DOI:
- 10.1093/noajnl/vdab070.012 ↗
- Languages:
- English
- ISSNs:
- 2632-2498
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 17577.xml